Immitra Bio raises CHF 2.4 M

Immitra Bio is developing an in vivo gene-editing platform that does not depend on the mutation, with a lead candidate against an inherited anaemia. It has raised CHF 2.4 million in pre-seed funding, including CHF 150,000 non-dilutive, led by Backbone Ventures and co-led by OCCIDENT, for preclinical studies.

Announced on
Round
Pre-seed
Amount
CHF 2.4 M
Location
Geneva
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic